AMR Centre, Shionogi team up for superbug therapy - PharmaTimeshttp://www.pharmatimes.com/news/amr_centre,_shionogi_team_up_for_superbug_therapy_1295005
2019-07 AMR Centre to license Shionogi COT-143 antibody
Alderley Park to run Japanese AMR therapy | Laboratory Newshttp://www.labnews.co.uk/article/2029874/alderley-park-to-run-japanese-amr-therapy
2019-07 AMR Centre to license Shionogi COT-143 antibody
Moving from push to pull | Laboratory Newshttps://www.labnews.co.uk/article/2030234/moving-from-push-to-pull
2019-07 AMR Centre to license Shionogi COT-143 antibody2019-10 Public Health England report on antibiotic resistance in EnglandAntibiotic resistance and pharmaceutical business models
Pharma companies AMR Centre and Shionogi in landmark deal to develop 'superbug' treatment - Business Livehttps://www.business-live.co.uk/enterprise/pharma-companies-amr-centre-shionogi-16627249
2019-07 AMR Centre to license Shionogi COT-143 antibody
Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa http://fs.magicalir.net/tdnet/2019/4507/20190722474070.pdf
2019-07 AMR Centre to license Shionogi COT-143 antibody
Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa | More News | News Channelshttps://pipelinereview.com/index.php/2019072371847/More-News/Shionogi-announces-out-licensing-agreement-with-AMR-Centre-on-COT-143-a-humanized-monoclonal-antibody-targeting-the-PcrV-protein-of-Pseudomonas-aeruginosa.html
2019-07 AMR Centre to license Shionogi COT-143 antibody

Showing topic

2019-07 AMR Centre to license Shionogi COT-143 antibody
Antibiotic resistance and the development of new drugsβ-lactam-resistant Pseudomonas aeruginosa